Rectal Delivery of a DNAzyme That Specifically Blocks the Transcription Factor GATA3 and Reduces Colitis in Mice

Vanessa Popp1, Katharina Gerlach1, Stefanie Mott1

  • 1Department of Medicine, University of Erlangen-Nürnberg, Kussmaul Research Campus, Erlangen, Germany.

Gastroenterology
|September 19, 2016
PubMed
Abstract

Insights

GATA3 is elevated in ulcerative colitis (UC) and drives inflammatory cytokine production. A GATA3-specific DNAzyme (hgd40) effectively reduced colitis in mice, suggesting potential for UC treatment.

Area of Science:

  • Immunology
  • Gastroenterology
  • Molecular Biology

Background:

  • GATA3 is a key transcription factor regulating T-cell cytokine production.
  • Investigated the role of GATA3 in the development of colitis.
  • GATA3 expression is linked to inflammatory responses in T cells.

Purpose of the Study:

  • To determine the role of GATA3 in colitis development.
  • To assess the therapeutic potential of targeting GATA3 in ulcerative colitis (UC).
  • To evaluate a GATA3-specific DNAzyme (hgd40) for colitis treatment.

Main Methods:

  • Quantitative PCR and immunofluorescence on human and mouse colon tissues.
  • Induction of colitis in mice using oxazolone or TNBS, with genetic modifications (GATA3 deletion, TNFR knockout).
  • Administration of GATA3-specific DNAzyme (hgd40) or control DNAzyme, anti-TNF antibody, and in vivo imaging.

Main Results:

  • GATA3 mRNA levels were higher in UC patients' colon tissues and correlated with inflammatory cytokines.
  • T-cell-specific GATA3 deletion prevented colitis development in mice.
  • The DNAzyme hgd40 inhibited GATA3 expression, reduced colitis, and decreased inflammatory cytokine levels in mice.

Conclusions:

  • GATA3 levels are elevated in UC and correlate with inflammatory cytokine production.
  • A GATA3-targeting DNAzyme (hgd40) effectively reduced colitis in mouse models, independent of TNF signaling.
  • The GATA3-specific DNAzyme hgd40 shows promise as a novel therapeutic agent for ulcerative colitis.